...
srpt-img

Sarepta Therapeutics Inc, Common Stock

SRPT

NSQ

$118.97

-$0.5

(-0.42%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$11.41B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
77.5779
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.39M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.80
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$91.34 L
$173.25 H
$118.97

About Sarepta Therapeutics Inc, Common Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSRPTSectorS&P500
1-Week Return-3.83%-2.12%-3%
1-Month Return7.32%-3.42%-0.73%
3-Month Return-6.48%-11.13%2.87%
6-Month Return-3.67%-5.74%7.17%
1-Year Return31.76%3.97%25.31%
3-Year Return33.66%1.05%28.38%
5-Year Return-5.71%34.37%81.89%
10-Year Return786.51%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue380.83M540.10M701.89M933.01M1.24B[{"date":"2019-12-31","value":30.63,"profit":true},{"date":"2020-12-31","value":43.44,"profit":true},{"date":"2021-12-31","value":56.45,"profit":true},{"date":"2022-12-31","value":75.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue56.59M63.38M97.05M139.99M150.34M[{"date":"2019-12-31","value":37.64,"profit":true},{"date":"2020-12-31","value":42.16,"profit":true},{"date":"2021-12-31","value":64.55,"profit":true},{"date":"2022-12-31","value":93.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit324.25M476.72M604.84M793.02M1.09B[{"date":"2019-12-31","value":29.67,"profit":true},{"date":"2020-12-31","value":43.62,"profit":true},{"date":"2021-12-31","value":55.34,"profit":true},{"date":"2022-12-31","value":72.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin85.14%88.26%86.17%85.00%87.91%[{"date":"2019-12-31","value":96.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.63,"profit":true},{"date":"2022-12-31","value":96.3,"profit":true},{"date":"2023-12-31","value":99.6,"profit":true}]
Operating Expenses846.57M1.04B1.05B1.33B1.36B[{"date":"2019-12-31","value":62.21,"profit":true},{"date":"2020-12-31","value":76.49,"profit":true},{"date":"2021-12-31","value":77.49,"profit":true},{"date":"2022-12-31","value":97.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(522.32M)(564.16M)(449.71M)(536.20M)(267.82M)[{"date":"2019-12-31","value":-52232300000,"profit":false},{"date":"2020-12-31","value":-56416300000,"profit":false},{"date":"2021-12-31","value":-44971000000,"profit":false},{"date":"2022-12-31","value":-53620100000,"profit":false},{"date":"2023-12-31","value":-26782400000,"profit":false}]
Total Non-Operating Income/Expense(214.99M)(45.88M)(22.41M)(190.52M)(208.08M)[{"date":"2019-12-31","value":-21498800000,"profit":false},{"date":"2020-12-31","value":-4587900000,"profit":false},{"date":"2021-12-31","value":-2240900000,"profit":false},{"date":"2022-12-31","value":-19052200000,"profit":false},{"date":"2023-12-31","value":-20807900000,"profit":false}]
Pre-Tax Income(713.88M)(553.07M)(418.95M)(689.96M)(520.10M)[{"date":"2019-12-31","value":-71388000000,"profit":false},{"date":"2020-12-31","value":-55306500000,"profit":false},{"date":"2021-12-31","value":-41894800000,"profit":false},{"date":"2022-12-31","value":-68996300000,"profit":false},{"date":"2023-12-31","value":-52009800000,"profit":false}]
Income Taxes1.20M1.06M(168.00K)13.53M15.88M[{"date":"2019-12-31","value":7.53,"profit":true},{"date":"2020-12-31","value":6.69,"profit":true},{"date":"2021-12-31","value":-1.06,"profit":false},{"date":"2022-12-31","value":85.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(715.08M)(554.13M)(418.78M)(703.49M)(535.98M)[{"date":"2019-12-31","value":-71507500000,"profit":false},{"date":"2020-12-31","value":-55412800000,"profit":false},{"date":"2021-12-31","value":-41878000000,"profit":false},{"date":"2022-12-31","value":-70348800000,"profit":false},{"date":"2023-12-31","value":-53597700000,"profit":false}]
Income From Continuous Operations(715.08M)(554.13M)(418.78M)(703.49M)(690.88M)[{"date":"2019-12-31","value":-71507500000,"profit":false},{"date":"2020-12-31","value":-55412800000,"profit":false},{"date":"2021-12-31","value":-41878000000,"profit":false},{"date":"2022-12-31","value":-70348800000,"profit":false},{"date":"2023-12-31","value":-69087600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(715.08M)(554.13M)(418.78M)(703.49M)(535.98M)[{"date":"2019-12-31","value":-71507500000,"profit":false},{"date":"2020-12-31","value":-55412800000,"profit":false},{"date":"2021-12-31","value":-41878000000,"profit":false},{"date":"2022-12-31","value":-70348800000,"profit":false},{"date":"2023-12-31","value":-53597700000,"profit":false}]
EPS (Diluted)(7.32)(6.49)(6.01)(8.03)(6.12)[{"date":"2019-12-31","value":-732,"profit":false},{"date":"2020-12-31","value":-649,"profit":false},{"date":"2021-12-31","value":-601,"profit":false},{"date":"2022-12-31","value":-803,"profit":false},{"date":"2023-12-31","value":-612,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SRPT
Cash Ratio 1.71
Current Ratio 3.84
Quick Ratio 3.03

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SRPT
ROA (LTM) 1.51%
ROE (LTM) 12.27%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SRPT
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SRPT
Trailing PE 77.76
Forward PE 9.62
P/S (TTM) 6.93
P/B 9.31
Price/FCF NM
EV/R 7.05
EV/Ebitda 61.77
PEG 159.25

FAQs

What is Sarepta Therapeutics Inc share price today?

Sarepta Therapeutics Inc (SRPT) share price today is $118.97

Can Indians buy Sarepta Therapeutics Inc shares?

Yes, Indians can buy shares of Sarepta Therapeutics Inc (SRPT) on Vested. To buy Sarepta Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SRPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sarepta Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Sarepta Therapeutics Inc (SRPT) via the Vested app. You can start investing in Sarepta Therapeutics Inc (SRPT) with a minimum investment of $1.

How to invest in Sarepta Therapeutics Inc shares from India?

You can invest in shares of Sarepta Therapeutics Inc (SRPT) via Vested in three simple steps:

  • Click on Sign Up or Invest in SRPT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sarepta Therapeutics Inc shares
What is Sarepta Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Sarepta Therapeutics Inc (SRPT) is $173.25. The 52-week low price of Sarepta Therapeutics Inc (SRPT) is $91.34.

What is Sarepta Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sarepta Therapeutics Inc (SRPT) is 77.5779

What is Sarepta Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sarepta Therapeutics Inc (SRPT) is 9.31

What is Sarepta Therapeutics Inc dividend yield?

The dividend yield of Sarepta Therapeutics Inc (SRPT) is 0.00%

What is the Market Cap of Sarepta Therapeutics Inc?

The market capitalization of Sarepta Therapeutics Inc (SRPT) is $11.41B

What is Sarepta Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Sarepta Therapeutics Inc is SRPT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top